Trial Profile
Dose Exploration in Patients With Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Aspirin; Warfarin
- Indications Cardiovascular disorders; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms PETRO; PETRO-Ex
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 15 Jan 2009 Extension study status changed from active, no longer recruiting to discontinued, as reported by clinicaltrials.gov.
- 15 Jan 2009 Extension study status changed from active, no longer recruiting to discontinued, as reported by clinicaltrials.gov.
- 11 Nov 2008 Long-term outcomes (mean 29 months follow-up) presented at the American Heart Association annual congress 2008.